Alivus Life Sciences reported a significant increase in Q4 EBITDA, reaching ₹2.1 billion, marking a year-on-year growth of 2%. The company also saw an improvement in its profit margins, rising to 31.1% from 30.6%, demonstrating a positive year-over-year progress of 0.6 percentage points.

Alivus Life Sciences reported a profit of ₹1,626 million and total income of ₹7,118.9 million for FY26. The board proposed a dividend of ₹5 per share, subject to shareholder approval at the AGM.

Alivus Life Sciences' Q4 performance remained unchanged compared to expectations, yet it still managed to achieve a record-breaking nine-month Profit After Tax (PAT) and Earnings Per Share (EPS). Despite previous growth, the quarter showed stability amidst challenging market conditions.

Alivus Life Sciences will release their Q4 and full-year 2026 results at a board meeting on May 14th. The meeting may also decide on a potential dividend payout. Trading restrictions are in effect from April 1st to May 16th.